Celsion Initiates First International Licensing Deal With Japan’s Yakult For Liver Cancer Drug ThermoDox
This article was originally published in PharmAsia News
Executive Summary
TOKYO -Yakult Honsha Co. of Tokyo and Celsion of Columbia, Md., announced a licensing agreement for Celsion's liver cancer drug ThermoDox, marking Celsion's first international licensing deal
You may also be interested in...
Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.
Biotech's primary liver cancer drug ThermoDox should produce pivotal Phase III data in the next 12 to 14 months.
Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.
Biotech's primary liver cancer drug ThermoDox should produce pivotal Phase III data in the next 12 to 14 months.
Celsion Signs Licensing Agreement With Japanese Yakult Honsha For Liver Cancer Agent ThermoDox
PERTH, Australia - Columbia, Md.-based biotech firm Celsion signed a licensing agreement with Japan's Yakult Honsha covering Celsion's liposomal platform drug, ThermoDox, a heat-sensitive formulation of doxorubicin to treat liver cancer